Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 4 of 4 entries
Sorted by: Best Match Show Resources per page
Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults.

Clinical and translational allergy

Fey C, Thyroff-Friesinger U, Jones S.
PMID: 25250173
Clin Transl Allergy. 2014 Sep 18;4:29. doi: 10.1186/2045-7022-4-29. eCollection 2014.

Montelukast is an effective and well-tolerated treatment for the prophylaxis and chronic treatment of asthma, acute prevention of exercise-induced bronchoconstriction and symptomatic relief of seasonal allergic rhinitis and perennial allergic rhinitis. The aim of the study was to compare...

Cite
Fey C, Thyroff-Friesinger U, Jones S. Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy. 2014;4:29doi: 10.1186/2045-7022-4-29.
Fey, C., Thyroff-Friesinger, U., & Jones, S. (2014). Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clinical and translational allergy, 429. https://doi.org/10.1186/2045-7022-4-29
Fey, Constanze, et al. "Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults." Clinical and translational allergy vol. 4 (2014): 29. doi: https://doi.org/10.1186/2045-7022-4-29
Fey C, Thyroff-Friesinger U, Jones S. Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy. 2014 Sep 18;4:29. doi: 10.1186/2045-7022-4-29. eCollection 2014. PMID: 25250173; PMCID: PMC4172315.
Copy Download .nbib Format: NLM
Clinical development of two innovative pharmaceutical forms of leuprorelin acetate.

Therapeutic advances in urology

Geiges G, Schapperer E, Thyroff-Friesinger U, Engert ZV, Gravel P.
PMID: 23372606
Ther Adv Urol. 2013 Feb;5(1):3-10. doi: 10.1177/1756287212471096.

OBJECTIVES: Two innovative pharmaceutical forms of leuprorelin acetate have been developed as 1-month and 3-month implants for the treatment of advanced hormone-dependent prostate cancer. These products contain active substance dispersed homogeneously in a biodegradable polymer. Here we present the...

Cite
Geiges G, Schapperer E, Thyroff-Friesinger U, et al. Clinical development of two innovative pharmaceutical forms of leuprorelin acetate. Ther Adv Urol. 2013;5(1):3-10doi: 10.1177/1756287212471096.
Geiges, G., Schapperer, E., Thyroff-Friesinger, U., Engert, Z. V., & Gravel, P. (2013). Clinical development of two innovative pharmaceutical forms of leuprorelin acetate. Therapeutic advances in urology, 5(1), 3-10. https://doi.org/10.1177/1756287212471096
Geiges, Goetz, et al. "Clinical development of two innovative pharmaceutical forms of leuprorelin acetate." Therapeutic advances in urology vol. 5,1 (2013): 3-10. doi: https://doi.org/10.1177/1756287212471096
Geiges G, Schapperer E, Thyroff-Friesinger U, Engert ZV, Gravel P. Clinical development of two innovative pharmaceutical forms of leuprorelin acetate. Ther Adv Urol. 2013 Feb;5(1):3-10. doi: 10.1177/1756287212471096. PMID: 23372606; PMCID: PMC3547534.
Copy Download .nbib Format: NLM
Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag).

Pharmacology research & perspectives

Schapperer E, Daumann H, Lamouche S, Thyroff-Friesinger U, Viel F, Weitschies W.
PMID: 25692005
Pharmacol Res Perspect. 2015 Feb;3(1):e00072. doi: 10.1002/prp2.72. Epub 2015 Jan 05.

The aim was to assess the bioequivalence of Sandoz methylphenidate osmotic-controlled release (OCR) tablets (Sandoz [Methylphenidate[ MPH OCR) with Concerta®, a methylphenidate formulation indicated for the treatment of attention deficit/hyperactivity disorder (ADHD). Four open-label, randomized, single-dose, two-way crossover bioequivalence...

Cite
Schapperer E, Daumann H, Lamouche S, et al. Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag). Pharmacol Res Perspect. 2015;3(1):e00072doi: 10.1002/prp2.72.
Schapperer, E., Daumann, H., Lamouche, S., Thyroff-Friesinger, U., Viel, F., & Weitschies, W. (2015). Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag). Pharmacology research & perspectives, 3(1), e00072. https://doi.org/10.1002/prp2.72
Schapperer, Elisabeth, et al. "Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag)." Pharmacology research & perspectives vol. 3,1 (2015): e00072. doi: https://doi.org/10.1002/prp2.72
Schapperer E, Daumann H, Lamouche S, Thyroff-Friesinger U, Viel F, Weitschies W. Bioequivalence of Sandoz methylphenidate osmotic-controlled release tablet with Concerta® (Janssen-Cilag). Pharmacol Res Perspect. 2015 Feb;3(1):e00072. doi: 10.1002/prp2.72. Epub 2015 Jan 05. PMID: 25692005; PMCID: PMC4317218.
Copy Download .nbib Format: NLM
Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.

Therapeutic advances in urology

Solarić M, Bjartell A, Thyroff-Friesinger U, Meani D.
PMID: 28588651
Ther Adv Urol. 2017 Apr 18;9(6):127-136. doi: 10.1177/1756287217701665. eCollection 2017 Dec.

BACKGROUND: There are two slow-release ready-to-use forms of leuprorelin acetate (1-month and 3-month) that are available as solid, biodegradable implants for the treatment of advanced, hormone-sensitive prostate cancer. These implants have been shown to be as effective as traditional...

Cite
Solarić M, Bjartell A, Thyroff-Friesinger U, et al. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. Ther Adv Urol. 2017;9(6):127-136doi: 10.1177/1756287217701665.
Solarić, M., Bjartell, A., Thyroff-Friesinger, U., & Meani, D. (2017). Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. Therapeutic advances in urology, 9(6), 127-136. https://doi.org/10.1177/1756287217701665
Solarić, Mladen, et al. "Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation." Therapeutic advances in urology vol. 9,6 (2017): 127-136. doi: https://doi.org/10.1177/1756287217701665
Solarić M, Bjartell A, Thyroff-Friesinger U, Meani D. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation. Ther Adv Urol. 2017 Apr 18;9(6):127-136. doi: 10.1177/1756287217701665. eCollection 2017 Dec. PMID: 28588651; PMCID: PMC5444576.
Copy Download .nbib Format: NLM
Showing 1 to 4 of 4 entries